{"entity":{"id":"ots-p22","kind":"drug","name":"OTS-P22","aka":[],"tldr":"OTS-P22 is an experimental peptide drug conjugate from Oncotherapy Solutions, being prepared for triple-negative breast cancer and other solid tumours. It has not yet been tested in people.","summary":"OTS-P22 is Oncotherapy Solutions' most advanced preclinical peptide drug conjugate. The company reports high stability in human plasma in vitro and complete tumour growth inhibition in an HCC1806 triple-negative breast cancer model in mice after one intravenous dose of 1.4 mg/kg, and plans IND-enabling studies for triple-negative breast, metastatic ovarian and endometrial cancers. No registered trial was found.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"Oncotherapy Solutions pipeline","url":"https://oncotherapysolutions.com/pipeline"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["oncotherapy-solutions"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"OTS-P22","modality":"Peptide drug conjugate","mechanism":"A peptide drug conjugate that, according to Oncotherapy Solutions, targets a receptor highly expressed in many solid tumours and carries a cytotoxic payload into the cell.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ots-p22/","neighbours":{"company":[{"id":"oncotherapy-solutions","kind":"company","name":"Oncotherapy Solutions","route":"/companies/oncotherapy-solutions/"}]}}